The aim of this clinical trial is to find out the safe dose (also called the maximum tolerated dose) of a drug called Eltrombopag when used in combination with Azacitidine in patients with Myelodysplastic Syndromes (MDS) and some types of Acute Myeloid Leukaemia (AML) and Chronic Myelomonocytic Leukaemia (CMML).
Please note that the trials team cannot give individuals clinical advice. Patients and their families should contact their treating physician to discuss trials for which they may be eligible
| Chief Investigator: |
Dr Alexander Sternberg |
| Sponsor: |
University of Birmingham |
| Funders: |
TAP, Bloodwise |
| Disease Site: |
AML, MDS |
| Trial Type: |
Clinical Trial of an Investigational Medicinal Product |
| Status: |
Open |
| UKCRN Study ID: (if applicable) |
14761 |
| Open to new sites? |
No |
| Recruitment start date: |
27-Nov-2014 |
| Anticipated Recruitment end date |
30-Sep-2016 |
| CRCTU Trial Management Team: |
Haematology |
| Trial E-mail Address: |
elastic@trials.bham.ac.uk |